Armata Pharmaceuticals reports Q3 2026 results, net income surge and FDA Breakthrough Therapy designation
Armata Pharmaceuticals posted a net income of $54.9 million for the quarter ended September 30, 2026, driven largely by a $69.6 million fair‑value gain on its convertible loan. Revenue was $3.17 million, up sharply from the prior year, and the company received an additional $3.7 million from the U.S. Department of War, bringing total non‑dilutive funding to about $32.4 million. The FDA granted Breakthrough Therapy designation to its AP‑SA02 candidate and the firm expects to start the Phase 3 superiority study in the second half of 2026, pending protocol concurrence.
Why it matters
The loan gain created a large quarterly profit despite modest operating revenue, which may affect cash flow expectations (the company’s press release notes the profit). The FDA designation and Phase 3 preparation de‑risk the product pipeline, potentially improving future valuation (the company states the designation underscores clinical potential).
Key facts
- 1Q3 2026 net income was $54.9 million. prnewswire.com
- 2Q3 2026 revenue was $3.17 million. tradingview.com
- 3The company recorded a $69.6 million fair‑value gain on its convertible loan. tradingview.com
- 4Armata received $3.7 million in additional DoW funding, bringing cumulative DoW funding to approximately $32.4 million. prnewswire.com
- 5The FDA granted Breakthrough Therapy designation to AP‑SA02 on September 14, 2026. tradingview.com
- 6The Phase 3 superiority study for AP‑SA02 is expected to initiate in the second half of 2026, subject to FDA protocol concurrence. prnewswire.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.